While 89bio continues to advance its key Phase 3 trial for its flagship drug candidate, Pegozafermin, the company has received a significant vote of confidence from the investment bank H.C. Wainwright. The firm has initiated coverage with a Buy rating and a price target of $32, betting on the therapy’s long-term potential. This optimistic outlook from analysts raises the question of whether investor enthusiasm can be sustained through the anticipated 2027 wait for pivotal data.
Strategic Hiring and a Competitive Landscape
Beyond the analyst excitement, 89bio is strengthening its internal team for the final development push. The company recently secured three new employees with stock option packages collectively worth over 64,000 shares. This move, which includes a four-year vesting period, is viewed as a strategic effort to align key personnel with the study’s success and ensure the critical Phase 3 program is driven forward with full momentum.
Should investors sell immediately? Or is it worth buying 89bio?
The focus remains squarely on Pegozafermin, an FGF21 analog designed to treat metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Market experts highlight the drug’s favorable tolerability profile and its bi-weekly dosing schedule as key differentiators that could provide a competitive edge in a multi-billion dollar market. However, the major catalyst for the stock is not expected until the Phase 3 data readout, which is projected for 2027 at the earliest.
A Test of Patience for Investors
The immediate calendar offers a near-term event for shareholders, with company leadership scheduled to present at the H.C. Wainwright Annual Global Investment Conference on September 8. Despite such appearances, the core challenge for 89bio and its investors is the protracted timeline. The intervening years will ultimately test whether the early analyst optimism is justified, long before the clinical results that will prove or disprove the drug’s efficacy are available.
Ad
89bio Stock: Buy or Sell?! New 89bio Analysis from December 9 delivers the answer:
The latest 89bio figures speak for themselves: Urgent action needed for 89bio investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 9.
89bio: Buy or sell? Read more here...
